Perioperative Biomarkers in Colorectal and Gastric Cancer Surgery
NCT07881133
Summary
This study aims to evaluate whether monitoring perioperative inflammatory and metabolic biomarkers can help identify postoperative complications early in adult patients undergoing colorectal or gastric cancer surgery. The study is a randomized controlled trial conducted at Bucharest Emergency Clinical Hospital, Romania. Participants are assigned to either an intervention group receiving enhanced recovery care (ERAS) combined with perioperative biomarker monitoring or a control group receiving standard postoperative care. The biomarkers of interest include procalcitonin, lactate, and blood glucose. The study will examine their relationship with postoperative complications, particularly infections and anastomotic leakage. Participants will be followed for 30 days after surgery to assess postoperative complications, hospital length of stay, readmissions, and mortality. The findings may help improve postoperative monitoring and support earlier recognition of complications in patients undergoing cancer surgery.
Eligibility
Inclusion Criteria: * Adult patients aged 18 years or older. * Patients diagnosed with colorectal or gastric cancer. * Patients scheduled for elective abdominal oncologic surgery. * Patients classified as ASA physical status II-IV. * Patients who provide written informed consent to participate in the study. Exclusion Criteria: * Patients with known autoimmune or immunological diseases that may significantly influence inflammatory biomarker levels. * Patients diagnosed with inflammatory bowel disease (IBD). * Patients who refuse to participate or do not provide written informed consent.
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07881133